Adverse events342

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 342

Type	Event	Organ system	Group	Affected	At risk
other	hemoglobin	Blood and lymphatic system disorders	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	38	82
other	hemoglobin	Blood and lymphatic system disorders	Phase II-Arm A Pts (Control Group): RT + TMZ	19	29
other	leukocytes	Blood and lymphatic system disorders	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	34	82
other	leukocytes	Blood and lymphatic system disorders	Phase II-Arm A Pts (Control Group): RT + TMZ	12	29
other	lymphopenia	Blood and lymphatic system disorders	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	43	82
other	lymphopenia	Blood and lymphatic system disorders	Phase II-Arm A Pts (Control Group): RT + TMZ	16	29
other	neutrophils	Blood and lymphatic system disorders	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	21	82
other	neutrophils	Blood and lymphatic system disorders	Phase II-Arm A Pts (Control Group): RT + TMZ	9	29
other	platelets	Blood and lymphatic system disorders	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	48	82
other	platelets	Blood and lymphatic system disorders	Phase II-Arm A Pts (Control Group): RT + TMZ	13	29
other	blood/bone marrow: other: decreased hematocrit	Blood and lymphatic system disorders	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	6	82
other	blood/bone marrow: other: decreased hematocrit	Blood and lymphatic system disorders	Phase II-Arm A Pts (Control Group): RT + TMZ	1	29
other	blood/bone marrow: other: decreased red blood cells	Blood and lymphatic system disorders	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	3	82
other	blood/bone marrow: other: decreased red blood cells	Blood and lymphatic system disorders	Phase II-Arm A Pts (Control Group): RT + TMZ	2	29
other	blood/bone marrow: other: increase eosinophils	Blood and lymphatic system disorders	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	2	82
other	blood/bone marrow: other: increase eosinophils	Blood and lymphatic system disorders	Phase II-Arm A Pts (Control Group): RT + TMZ	2	29
other	PTT	Investigations	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	5	82
other	PTT	Investigations	Phase II-Arm A Pts (Control Group): RT + TMZ	1	29
other	fatigue	General disorders	Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib	62	82
other	fatigue	General disorders	Phase II-Arm A Pts (Control Group): RT + TMZ	22	29

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00441142/events

API reference For AI assistants

Adverse events342

Sources 3

Read this list from software.